Percentageneeded to beconsidered HR+(adjuvantendocrine therapyconsidered)AromataseinhibitorsLVEFmonitoringChemoendocrinetherapyPembrolizumabOlaparibCapecitabineEverymonthTaxanes10yearsTNBC2yearsVenlafaxineTC (docetaxel /cyclophosphamide)TamoxifenRadiationtherapy1yearTDM-1(Ado-trastuzumabemtansine)ExemestaneAnthracyclinesPertuzumabLoperamideprophylaxisAbemaciclibIntermediate(11-25)Percentageneeded to beconsidered HR+(adjuvantendocrine therapyconsidered)AromataseinhibitorsLVEFmonitoringChemoendocrinetherapyPembrolizumabOlaparibCapecitabineEverymonthTaxanes10yearsTNBC2yearsVenlafaxineTC (docetaxel /cyclophosphamide)TamoxifenRadiationtherapy1yearTDM-1(Ado-trastuzumabemtansine)ExemestaneAnthracyclinesPertuzumabLoperamideprophylaxisAbemaciclibIntermediate(11-25)

Early-Stage Breast Cancer - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. Percentage needed to be considered HR+ (adjuvant endocrine therapy considered)
  2. Aromatase inhibitors
  3. LVEF monitoring
  4. Chemoendocrine therapy
  5. Pembrolizumab
  6. Olaparib
  7. Capecitabine
  8. Every month
  9. Taxanes
  10. 10 years
  11. TNBC
  12. 2 years
  13. Venlafaxine
  14. TC (docetaxel / cyclophosphamide)
  15. Tamoxifen
  16. Radiation therapy
  17. 1 year
  18. TDM-1 (Ado-trastuzumab emtansine)
  19. Exemestane
  20. Anthracyclines
  21. Pertuzumab
  22. Loperamide prophylaxis
  23. Abemaciclib
  24. Intermediate (11-25)